Russell Andrews Reveals ALS Diagnosis
Digest more
"There's so much more to learn, more to do, and we have to do it now," Dane said in an I AM ALS public service announcement released on Monday.
The FDA has granted Coya 302 a fast-track designation for ALS, according to a press release from Coya Therapeutics. “ALS is a pretty devastating disease,” Fred Grossman, DO, FAPA, president and chief medical officer of Coya Therapeutics,